How did PHVS perform in Q4 2023 earnings?

Pharvaris N.V. (PHVS) experienced a net loss of €134.2 million for the fourth quarter of 2024, with a reported EPS of -0.73 and zero revenue estimated for the period ending December 31, 2024. The company's financial results for Q4 2024 reflect its ongoing investment in clinical development, despite maintaining a strong financial position with €281 million in cash and cash equivalents as of December 31, 2024. 1. **Financial Performance**: Pharvaris N.V. reported a net loss of €134.2 million for Q4 2024, which is a significant indicator of the company's financial challenges. The reported EPS of -0.73 for the quarter suggests that the company has not yet achieved profitability, aligning with the expectations of analysts who forecasted a loss of ($0.54) per share for the quarter. 2. **Cash Position and R&D Expenses**: Despite the net loss, Pharvaris N.V. maintained a strong cash position with €281 million in cash and cash equivalents as of December 31, 2024. This financial strength is crucial for the company's continued investment in research and development (R&D), which totaled €98.6 million for the year. 3. **Business Progress**: Pharvaris achieved target enrollment in its pivotal Phase 3 RAPIDe-3 study for the on-demand treatment of HAE attacks and is progressing with the CHAPTER-3 study for prophylaxis of HAE attacks, with topline data expected in the second half of 2026. The European Commission granted orphan medicinal product designation to their lead candidate, deucrictibant, reinforcing its potential in treating bradykinin-mediated angioedema. 4. **Analyst Ratings and Price Target**: Analysts have provided mixed ratings and price targets for Pharvaris N.V. stock. While some analysts have set bullish targets, such as JMP Securities and Wedbush, others have adjusted their targets downward, reflecting the uncertainty surrounding the company's financial performance and the broader biotech market. In conclusion, Pharvaris N.V. faced significant financial challenges in Q4 2024, with a net loss of €134.2 million and a reported EPS of -0.73. However, the company's strong cash position and ongoing progress in clinical development provide a basis for optimism. Analysts have provided a range of ratings and price targets, reflecting the complexity of evaluating a pre-revenue biotech firm like Pharvaris.